Geistlich Pharma Granted FDA Breakthrough Device Designation for Chondro-Gide® Articular Cartilage C
WOLHUSEN, Switzerland--(BUSINESS WIRE)--Geistlich Pharma, a Swiss developer of biomaterials for regenerative therapies in orthopedics, announced that the Chondro-Gide® articular cartilage cover has been granted a Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration. Chondro-Gide® is a col...